The study was performed independently by investigators at the US Food and Drug Administration (FDA), Center for Biologics Evaluation and Research
EMA’s CHMP advice states that Paxlovid can be used for treatment of adults with Covid-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe disease
Since its launch, the medical devices park in Sultanpur has received overwhelming response with more than 50 companies lining up to set up their manufacturing or research and development units
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
The cash consideration for the acquisition is US$ 18 million.
The data has been shared with the U.S.FDA as part of an ongoing rolling submission for Emergency Use Authorisation
During H1 FY2022, the revenues and operating profit margin (OPM) for ICRA sample set showed sharp improvement aided by volume uptick in Covid-19 and allied tests and also demand traction for non-Covid tests
It accelerates the company’s vision for transforming healthcare and advancing patient care worldwide – from the hospital to the home
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
FDA changes inspection classification of the facility to Voluntary Action Indicated
The campaign “Care is Just An Aster Away” was launched along with the unveiling of the new corporate logo on Burj Khalifa on 11th December
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
The total cost of the project is estimated at Rs 30 crore
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron
The Uteshiya facility, licensed by Healthium, will exclusively manufacture Healthium’s arthroscopy portfolio, including patented products in India and U.S.
Organised by the Indian Stroke Association, it has attracted over 800 doctors from India and overseas
This is the fourth facility from the company to receive this registration
.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Subscribe To Our Newsletter & Stay Updated
